Related Experiment Video
Updated: Apr 13, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Biomarkers of Alzheimer's disease pathophysiology and delirium
Kristi Henjum1, Bjørn Erik Neerland2, Kaj Blennow3
1Oslo Delirium Research Group, Institute of Clinical Medicine, University of Oslo, 0318, Oslo, Norway.
Background:
Alzheimer's disease (AD) is characterised by amyloid-beta (A) and tau (T) pathology, and neurodegeneration (N). AT(N) neuropathology precedes the symptomatic presentation of the disease. This asymptomatic phase may present vulnerability towards delirium, but studies are inconclusive. In this cross-sectional study of hip fracture patients, we aimed to explore the association between AD biomarkers for AT(N) neuropathology and delirium, with focus on patients without clinical dementia.
Methods:
The AT(N) biomarkers were analysed in cerebrospinal fluid (CSF) in hip fracture patients (n = 401). Pre-fracture dementia was defined by IQCODE ≥3.44 (n = 164). Delirium was diagnosed according to the DSM-5 criteria. The CSF concentrations of amyloid-beta1-42 (Aβ42), amyloid-beta1-40 (Aβ40), phosphorylated tau181 (p-tau) and total-tau (t-tau) were quantified by Lumipulse G assays (Fujirebo, Ghent, Belgium). The Aβ42/Aβ40 ratio (cutoff A+ <0.72), p-tau181 (T+ >50 pg/ml) and t-tau (N+ >409 pg/ml) were used to determine A, T and N status, respectively.
Findings:
Hip fracture patients with delirium had lower CSF Aβ42 concentrations and higher concentrations of CSF p-tau and CSF t-tau than those without delirium (student's t-test, all p-values <0.001). Brain Aβ-deposition, A+ was more common in patients with delirium (χ2 p < 0.001). In patients without pre-fracture dementia, delirium was associated with lower CSF Aβ42 concentrations (student's t-test, p = 0.005), and higher CSF concentrations of p-tau (student's t-test p = 0.004) and t-tau (student's t-test p = 0.002). A higher proportion developed delirium among those A+T+ (33%) compared to A-T- (17%, χ2 p = 0.02).
Interpretation:
These findings support that the AD AT neuropathology is a risk factor for delirium in patients without clinical dementia.
Funding:
South-Eastern Norway Regional Health Authorities (# 2017095), the Norwegian Health Association (#16149, #19536, #1513) and by Wellcome Leap's Dynamic Resilience Program (jointly funded by Temasek Trust) (#104617).
More Related Videos
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Dementia
The progression of dementia is generally gradual....
Parkinson's Disease: Overview